IRCT20201229049873N1CompletedPhase 2
?Investigation of Anti-TNF-a (Infliximab) drug effectiveness in COVID-19 patients
Shahre-kord University of Medical Sciences0 sites40 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •Patients with Covid-19 with acute respiratory symptoms between the ages of 18 and 60 who test positive for the SARS-CoV-19 virus by RT-PCR or by CT scan. Lung scan (subpleural lung involvement, bilateral circumference, and more than one area).
- •Saturated oxygen is below 88%
- •Respiratory rate more than 24 times per minute
- •high CRP and D-dimer level, also ferritin above 1000
- •Lymphopenia with a count of less than 1100
Exclusion Criteria
- •Patients who have a positive test for PPD, HCV, HBS
- •Patients Have a history of neurodegenerative diseases such as multiple sclerosis
- •Patients with heart failure, hypertension, and infections other than Covid 19 infection.
Investigators
Similar Trials
Completed
Not Applicable
Infliximab(anti human TNF alfa monoclonal antibody, Remicade) off-label treatment for refractory Kawasaki diseaseKawasaki diseaseJPRN-UMIN000007423Department of Pediatrics, Saitama Medical Center, Saitama Medical University5
Completed
Phase 3
A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid ArthritisRheumatoid ArthritisNCT00236028Centocor, Inc.607
Completed
Phase 2
A study of infliximab administration method for tacrolimus-resistant active ulcerative colitisulcerative colitisJPRN-UMIN000013716Yokohama City University Medical Center40
Completed
Not Applicable
"Effect examination of infliximab to the effect insufficient example and the example of effect decrease of the 1st TNF inhibitor in rheumatoid arthritis "Rheumatoid ArthritisJPRN-UMIN000007786Saitama Medical Center. Saitama Medical University40
Completed
Phase 3
Infliximab Plus Methotrexate for the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00269867Centocor, Inc.428